Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 4, Pp 33-35 (2018)

Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’), 2018.

аутоантитела, белок s-100, nmda-рецепторы, дофаминовые рецепторы, паркинсонизм, эпилепсия, шизофрения, antibodies, protein s-100, nmda-receptors, dopamine receptors, parkinsonism, epilepsy, schizophrenia, Medicine (General), R5-920

The blood plasma IgG autoantibodies to human protein S-100, to NMDA-receptors and to dopamine receptor type 2 were determined in 13 epilepsy patients with secondary generalized seizures, 16 - in Parkinson patients, 33 - in schizophrenia patients at the age of 18-78. All the enrollees were male. The level of antibodies to S-100 in patients with Parkinson’s was close to normal, it was increased in epilepsy patients and in 59 % of schizophrenia patients. Herewith, in 41 % of schizophrenia patients the levels of autoantibodies to protein S-100 were within normal range. The level of autoantibodies to NMDA-receptors was moderately increased in patients with Parkinson’s and noticeably increased in patients with epilepsy. 45 % of patients with schizophrenia showed a significant increase in NMDA receptor autoantibodies, the others - had normal levels of antibodies. The level of autoantibodies to dopamine receptors in patients with Parkinson’s was normal, and in patients with epilepsy it was significantly increased. In 21 % of patients with schizophrenia the level of autoantibodies to dopamine receptors was normal and in 79 % of patients had significantly increased level of autoantibodies. In patients with schizophrenia high levels of antibodies to dopamine receptors overlapped with high levels of autoantibodies to S-100.